Dr. Tashko’s badge from the Better Business Bureau displays an “Accredited Business” seal with an A+ rating as of July 9, 2025 for GT Health practice. The design features the BBB torch logo on the left and a clickable prompt for profile access on the right, reinforcing professional credibility, transparency, and excellence in patient care and business ethics.
🗨️ Text Us Securely

Fees | Join Our Practice

Dr. Tashko’s 3D infographic depicting lipoprotein(a) history from 1963 to the present. A textured blue particle with a red, devil-like tail symbolizes Lp(a)’s enduring role as a hidden cardiovascular risk factor. The deep red and blue tones evoke decades of research linking this molecule to heart disease and arterial inflammation.

Lipoprotein(a), or Lp(a), is one of the most intriguing molecules in cardiovascular research. Though less known than LDL or HDL cholesterol, its role in heart disease is undeniable. Understanding its history reveals how science has gradually unraveled its significance and potential for treatment.

The Discovery of Lipoprotein(a)

In 1963, Norwegian scientist Dr. Kåre Berg discovered Lp(a) while studying inherited traits in families. He identified a unique plasma lipoprotein linked to cardiovascular disease. Unlike other cholesterol molecules, Lp(a) levels were determined almost entirely by genetics, making it a groundbreaking find.

This genetic nature set Lp(a) apart and hinted at its importance in understanding heart disease. As research advanced, its structure revealed even more complexity.

Structural Insights: A Unique Hybrid Molecule

By the 1970s, researchers began dissecting Lp(a)’s complex structure. It combined an LDL cholesterol particle with a unique protein called apolipoprotein(a), or apo(a). This protein resembled plasminogen, a molecule involved in breaking down blood clots.

This similarity suggested Lp(a) could interfere with clot breakdown, increasing the risk of thrombosis. These properties distinguished Lp(a) from LDL, linking it to both plaque buildup and clotting risks. Researchers soon turned their focus to Lp(a)’s genetic underpinnings.

The Genetic Puzzle of Lp(a)

In the 1990s, genetic research revealed that the LPA gene controlled Lp(a) levels and structure. Smaller versions of apo(a) led to higher Lp(a) levels and greater cardiovascular risks. Unlike LDL, lifestyle changes barely affected Lp(a), frustrating efforts to manage it.

Researchers also found significant differences across ethnic groups, with African populations having higher levels. These findings led to larger studies investigating Lp(a) as a cardiovascular risk.

Establishing Lp(a) as a Cardiovascular Risk Factor

By the 2000s, large-scale studies confirmed Lp(a)’s connection to heart disease. Elevated levels increased the risk of heart attacks, strokes, and aortic valve stenosis. Unlike LDL, Lp(a) contributed to disease through inflammation, clot formation, and arterial damage.

A 2009 landmark study in JAMA analyzed data from over 125,000 participants. It confirmed that high Lp(a) levels independently raised the risk of coronary heart disease. This landmark study confirmed Lp(a)’s link to coronary heart disease. However, addressing elevated Lp(a) levels posed significant challenges.

Challenges in Treating High Lp(a)

Managing Lp(a) has proven difficult. Statins, which effectively lower LDL cholesterol, have little effect on Lp(a). This limitation left patients with elevated Lp(a) levels few options.

Niacin, an older cholesterol-lowering drug, showed moderate success in reducing Lp(a). However, side effects and inconsistent results made it less favorable for long-term use. For decades, this lack of targeted treatments frustrated clinicians and patients.

The Era of Precision Medicine

The 2010s brought advances in genetic therapies, offering new hope for Lp(a) management. Scientists developed antisense oligonucleotides (ASOs), which block the production of apo(a) at the genetic level.

Drugs like pelacarsen, an ASO targeting Lp(a), have shown promise in clinical trials. They reduced Lp(a) levels by up to 80%, potentially transforming care for high-risk patients. These therapies represent a breakthrough after years of limited progress. With new tools available, the medical community began integrating Lp(a) into clinical medicine.

Lp(a) in Clinical Practice Today

Today, Lp(a) is recognized as a significant atherosclerosis risk factor. Major health organizations, including the American Heart Association, recommend measuring Lp(a) in certain high-risk patients. Increased awareness among doctors and patients is driving better risk assessment and early intervention.

Although testing for Lp(a) is not yet routine, growing awareness and ongoing research signal hope for the future. As precision medicine evolves, these barriers will likely diminish, opening doors to better prevention and care.

Summary

The history of Lp(a) reflects decades of scientific curiosity and persistence. From its discovery in 1963 to today’s cutting-edge genetic therapies, Lp(a) has traveled from obscurity to prominence. Its unique role in cardiovascular health has challenged researchers but also inspired innovation.

As science continues to unlock its mysteries, Lp(a) offers hope for more personalized approaches to preventing and treating heart disease.

Dr. Tashko

For Personalized Lipid and Lp(a) Care,
Join Dr. Tashko’s Practice!
Logo for the Clinical Lipidology Board Certification (ABCL)

References:

  1. Kostner KM, Kostner GM. Lipoprotein(a): a historical appraisal. J Lipid Res. 2016;57(1):1-14. doi:10.1194/jlr.R071571.
  2. Wang XL, Wilcken DE, Dudman NP. Early expression of the apolipoprotein(a) gene: relationships between infants’ and their parents’ serum apolipoprotein(a) levels. Pediatrics. 1992;89(3):401-6.  
  3. Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein(a). J Lipid Res. 2016;57(8):1339-59. doi:10.1194/jlr.R067314. 
  4. Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A genetically determined, causal, and nonmodifiable risk factor for atherosclerotic cardiovascular disease and aortic stenosis. Arterioscler Thromb Vasc Biol. 2021;41(7):1769-1785. doi:10.1161/ATVBAHA.120.315936
  5. Kronenberg F, Kronenberg MF, Kiechl S, et al. Role of Lipoprotein(a) and Apolipoprotein(a) Phenotype in Atherogenesis: Prospective Results From the Bruneck Study. Circulation. 1999;100(11):1154-1160. doi:10.1161/01.cir.100.11.1154  
  6. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412-23. doi:10.1001/jama.2009.1063.  
  7. Scanu AM, Bamba R. Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations. Am J Cardiol. 2008;101(8A):44B-47B. doi:10.1016/j.amjcard.2008.02.031.
  8. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med. 2020;382(4):244-255. doi:10.1056/NEJMoa1905239.  
  9. Tashko G. Atherosclerosis: The Most Common Silent Threat. Gerti Tashko MD. https://gertitashkomd.com/atherosclerosis-the-most-common-silent-threat/
  10. Precision Medicine Initiative (PMI) Working Group. NIH Advisory Committee to the Director. https://acd.od.nih.gov/working-groups/pmi.html

About Dr. Gerti Tashko, MD

Dr. Gerti Tashko, MD, is a board-certified endocrinologist based in Montgomery County, Maryland. He is uniquely certified in endocrinology, lipidology, hypertension, and obesity medicine. His practice offers comprehensive, root-cause-focused metabolic and endocrine care, available both virtually and in person. He uses advanced diagnostics, personalized nutrition, and preventive medicine to optimize long-term health outcomes.

Published

By

Gerti Tashko, MD
Categorized as , , ,